Reprotect Buffergel Phase II Data May Serve As Basis For NDA
This article was originally published in The Tan Sheet
Executive Summary
Data from a Phase II study on the contraceptive efficacy of Reprotect's Buffergel polyacrylic acid may serve as the basis for an eventual NDA filing by the firm. A Phase II trial of the gel's efficacy in preventing pregnancy may begin within the next six months.
You may also be interested in...
Vaginal Lubricants’ Ability To Kill HIV Merits Human Study – Researchers
Clinical trials testing the protective effect of three FDA-approved vaginal lubricants and preparations against HIV should be conducted in populations at high-risk for contracting the virus, University of Texas Medical Branch at Galveston researchers state
Vaginal Lubricants’ Ability To Kill HIV Merits Human Study – Researchers
Clinical trials testing the protective effect of three FDA-approved vaginal lubricants and preparations against HIV should be conducted in populations at high-risk for contracting the virus, University of Texas Medical Branch at Galveston researchers state
Vaginal Lubricants’ Ability To Kill HIV Merits Human Study – Researchers
Clinical trials testing the protective effect of three FDA-approved vaginal lubricants and preparations against HIV should be conducted in populations at high-risk for contracting the virus, University of Texas Medical Branch at Galveston researchers state